Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles
Purpose Myricetin (MYR) flavonoid is well-recognized for its antioxidant, anti-inflammatory and anti-tumor potential. Introducing nanomedicine was the ultimate resort to solve the imperfections of this nutraceutical, namely solubility, stability and delivery issues. The study, thus, aims at developi...
Gespeichert in:
| Veröffentlicht in: | Pharmaceutical research 2020-04, Vol.37 (4), p.82, Article 82 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 82 |
| container_title | Pharmaceutical research |
| container_volume | 37 |
| creator | Nafee, Noha Gaber, Dina M. Elzoghby, Ahmed O. Helmy, Maged W. Abdallah, Osama Y. |
| description | Purpose
Myricetin (MYR) flavonoid is well-recognized for its antioxidant, anti-inflammatory and anti-tumor potential. Introducing nanomedicine was the ultimate resort to solve the imperfections of this nutraceutical, namely solubility, stability and delivery issues. The study, thus, aims at developing inhalable microparticles comprising MYR solid lipid nanoparticles (SLNs) for lung cancer therapy.
Methods
A two-step preparation procedure starting with complexation of MYR with the phospholipid Lipoid-S100, followed by nanoencapsulation in Gelucire-based, surfactant-free SLNs was developed. SLNs were characterized in terms of physicochemical properties, MYR loading, release behavior as well as anti-tumor potential and cellular uptake. Respirable microparticles were then obtained by spray drying SLNs with carbohydrate carriers. Their size, flowability and pulmonary deposition pattern were assessed.
Results
Optimized SLNs were 75.98 nm in diameter with a zeta-potential of −22.5 mV, and an encapsulation efficiency of 84.5%. Attempts to ameliorate drug loading implicate MYR-phospholipid complexation (MYR-PH-CPX) prior to its entrapment in SLNs, which ensured 5-fold increase in drug loading. Viability assays were modified to guarantee MYR chemical stability. Superior antitumor activity of MYR-phospholipid-complex and 3-fold reduction in IC
50
were accomplished with MYR-SLNs. This could be related to enhanced cellular uptake revealed by confocal imaging and doubled fluorescence intensity. SLNs entrapping MYR-PH-CPX were spray-dried with carbohydrate carriers to produce respirable microparticles. The latter ensured MMAD of 2.39 μm and span index of 1.84, in addition to good flowability and > 80% release over 8 h. Deposition experiments revealed MMAD of 2.77 μm, FPF of 81.23 and EF of 93% indicating particle deposition in the targeted bronchial region.
Conclusions
The study highlights the ability of phospholipid-complex on the nanoencapsulation, cellular uptake and antitumor activity of MYR. Formulation of respirable microparticles gives promises of efficacious therapy of lung carcinoma. |
| doi_str_mv | 10.1007/s11095-020-02794-z |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2389522987</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A747438906</galeid><sourcerecordid>A747438906</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-80e1454a1cdfa07df407244ef57c56ff404a404e537dfd6be55779542bc023783</originalsourceid><addsrcrecordid>eNp9UV1rFDEUDaLYbfUP-CABn6cmmWQz87gsfhS2WkTFt5DN3NneMpOMSUbc_gB_t1m3WgSRcAk395yTnBxCnnF2zhnTLxPnrFUVE6yUbmV1-4AsuNJ11TL55SFZMC1k1WjJT8hpSjeMsYa38jE5qYVouRJsQX5cxTCGDB1d-Yx5HkOkK5fxG-Y9DT293Ed0kNFTu7PoU6ab2e_o2kaHPoyWfkZL31kfwDs7pXmwB62r65Cm6zDghB1dh3Ea4DstGh8gTRjtdgB6iS6GycaMboD0hDzq7ZDg6d1-Rj69fvVx_bbavH9zsV5tKqdYk6uGAZdKWu663jLd9fJgUUKvtFPLvrTSlgJVl1m33IJSWrdKiq1jotZNfUZeHHWnGL7OkLK5CXP05Uoj6qZV5V8afY_a2QEM-j7kaN2IyZmVlloWJFsW1Pk_UGV1MKILHnos538RxJFQnKcUoTdTxNHGveHMHBI1x0RNSdT8StTcFtLzuxfP2xG6P5TfERZAfQSkMvI7iPeW_iP7E4udrUg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2389522987</pqid></control><display><type>article</type><title>Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Nafee, Noha ; Gaber, Dina M. ; Elzoghby, Ahmed O. ; Helmy, Maged W. ; Abdallah, Osama Y.</creator><creatorcontrib>Nafee, Noha ; Gaber, Dina M. ; Elzoghby, Ahmed O. ; Helmy, Maged W. ; Abdallah, Osama Y.</creatorcontrib><description>Purpose
Myricetin (MYR) flavonoid is well-recognized for its antioxidant, anti-inflammatory and anti-tumor potential. Introducing nanomedicine was the ultimate resort to solve the imperfections of this nutraceutical, namely solubility, stability and delivery issues. The study, thus, aims at developing inhalable microparticles comprising MYR solid lipid nanoparticles (SLNs) for lung cancer therapy.
Methods
A two-step preparation procedure starting with complexation of MYR with the phospholipid Lipoid-S100, followed by nanoencapsulation in Gelucire-based, surfactant-free SLNs was developed. SLNs were characterized in terms of physicochemical properties, MYR loading, release behavior as well as anti-tumor potential and cellular uptake. Respirable microparticles were then obtained by spray drying SLNs with carbohydrate carriers. Their size, flowability and pulmonary deposition pattern were assessed.
Results
Optimized SLNs were 75.98 nm in diameter with a zeta-potential of −22.5 mV, and an encapsulation efficiency of 84.5%. Attempts to ameliorate drug loading implicate MYR-phospholipid complexation (MYR-PH-CPX) prior to its entrapment in SLNs, which ensured 5-fold increase in drug loading. Viability assays were modified to guarantee MYR chemical stability. Superior antitumor activity of MYR-phospholipid-complex and 3-fold reduction in IC
50
were accomplished with MYR-SLNs. This could be related to enhanced cellular uptake revealed by confocal imaging and doubled fluorescence intensity. SLNs entrapping MYR-PH-CPX were spray-dried with carbohydrate carriers to produce respirable microparticles. The latter ensured MMAD of 2.39 μm and span index of 1.84, in addition to good flowability and > 80% release over 8 h. Deposition experiments revealed MMAD of 2.77 μm, FPF of 81.23 and EF of 93% indicating particle deposition in the targeted bronchial region.
Conclusions
The study highlights the ability of phospholipid-complex on the nanoencapsulation, cellular uptake and antitumor activity of MYR. Formulation of respirable microparticles gives promises of efficacious therapy of lung carcinoma.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1007/s11095-020-02794-z</identifier><identifier>PMID: 32291520</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>A549 Cells ; Administration, Inhalation ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - metabolism ; Antineoplastic Agents - pharmacology ; Antioxidants ; Antitumor activity ; Biochemistry ; Bioflavonoids ; Biomedical and Life Sciences ; Biomedical Engineering and Bioengineering ; Biomedicine ; Cancer ; Carcinoma ; Cell Survival - drug effects ; Drug Carriers - chemistry ; Drug Compounding ; Drug Liberation ; Drying ; Flavones ; Flavonoids ; Flavonoids - administration & dosage ; Flavonoids - metabolism ; Flavonoids - pharmacology ; Functional foods ; Humans ; Inflammation ; Lung cancer ; Lung carcinoma ; Lung Neoplasms - drug therapy ; Medical Law ; Microparticles ; Nanoparticles ; Nanoparticles - chemistry ; Nanotechnology ; Particle Size ; Pharmacology/Toxicology ; Pharmacy ; Phospholipids ; Phospholipids - chemistry ; Physicochemical properties ; Research Paper ; Solubility ; Surface active agents ; Surface Properties ; Tissue Distribution</subject><ispartof>Pharmaceutical research, 2020-04, Vol.37 (4), p.82, Article 82</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-80e1454a1cdfa07df407244ef57c56ff404a404e537dfd6be55779542bc023783</citedby><cites>FETCH-LOGICAL-c508t-80e1454a1cdfa07df407244ef57c56ff404a404e537dfd6be55779542bc023783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11095-020-02794-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11095-020-02794-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32291520$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nafee, Noha</creatorcontrib><creatorcontrib>Gaber, Dina M.</creatorcontrib><creatorcontrib>Elzoghby, Ahmed O.</creatorcontrib><creatorcontrib>Helmy, Maged W.</creatorcontrib><creatorcontrib>Abdallah, Osama Y.</creatorcontrib><title>Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><addtitle>Pharm Res</addtitle><description>Purpose
Myricetin (MYR) flavonoid is well-recognized for its antioxidant, anti-inflammatory and anti-tumor potential. Introducing nanomedicine was the ultimate resort to solve the imperfections of this nutraceutical, namely solubility, stability and delivery issues. The study, thus, aims at developing inhalable microparticles comprising MYR solid lipid nanoparticles (SLNs) for lung cancer therapy.
Methods
A two-step preparation procedure starting with complexation of MYR with the phospholipid Lipoid-S100, followed by nanoencapsulation in Gelucire-based, surfactant-free SLNs was developed. SLNs were characterized in terms of physicochemical properties, MYR loading, release behavior as well as anti-tumor potential and cellular uptake. Respirable microparticles were then obtained by spray drying SLNs with carbohydrate carriers. Their size, flowability and pulmonary deposition pattern were assessed.
Results
Optimized SLNs were 75.98 nm in diameter with a zeta-potential of −22.5 mV, and an encapsulation efficiency of 84.5%. Attempts to ameliorate drug loading implicate MYR-phospholipid complexation (MYR-PH-CPX) prior to its entrapment in SLNs, which ensured 5-fold increase in drug loading. Viability assays were modified to guarantee MYR chemical stability. Superior antitumor activity of MYR-phospholipid-complex and 3-fold reduction in IC
50
were accomplished with MYR-SLNs. This could be related to enhanced cellular uptake revealed by confocal imaging and doubled fluorescence intensity. SLNs entrapping MYR-PH-CPX were spray-dried with carbohydrate carriers to produce respirable microparticles. The latter ensured MMAD of 2.39 μm and span index of 1.84, in addition to good flowability and > 80% release over 8 h. Deposition experiments revealed MMAD of 2.77 μm, FPF of 81.23 and EF of 93% indicating particle deposition in the targeted bronchial region.
Conclusions
The study highlights the ability of phospholipid-complex on the nanoencapsulation, cellular uptake and antitumor activity of MYR. Formulation of respirable microparticles gives promises of efficacious therapy of lung carcinoma.</description><subject>A549 Cells</subject><subject>Administration, Inhalation</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - metabolism</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antioxidants</subject><subject>Antitumor activity</subject><subject>Biochemistry</subject><subject>Bioflavonoids</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Carcinoma</subject><subject>Cell Survival - drug effects</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Compounding</subject><subject>Drug Liberation</subject><subject>Drying</subject><subject>Flavones</subject><subject>Flavonoids</subject><subject>Flavonoids - administration & dosage</subject><subject>Flavonoids - metabolism</subject><subject>Flavonoids - pharmacology</subject><subject>Functional foods</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Lung cancer</subject><subject>Lung carcinoma</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Medical Law</subject><subject>Microparticles</subject><subject>Nanoparticles</subject><subject>Nanoparticles - chemistry</subject><subject>Nanotechnology</subject><subject>Particle Size</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Phospholipids</subject><subject>Phospholipids - chemistry</subject><subject>Physicochemical properties</subject><subject>Research Paper</subject><subject>Solubility</subject><subject>Surface active agents</subject><subject>Surface Properties</subject><subject>Tissue Distribution</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9UV1rFDEUDaLYbfUP-CABn6cmmWQz87gsfhS2WkTFt5DN3NneMpOMSUbc_gB_t1m3WgSRcAk395yTnBxCnnF2zhnTLxPnrFUVE6yUbmV1-4AsuNJ11TL55SFZMC1k1WjJT8hpSjeMsYa38jE5qYVouRJsQX5cxTCGDB1d-Yx5HkOkK5fxG-Y9DT293Ed0kNFTu7PoU6ab2e_o2kaHPoyWfkZL31kfwDs7pXmwB62r65Cm6zDghB1dh3Ea4DstGh8gTRjtdgB6iS6GycaMboD0hDzq7ZDg6d1-Rj69fvVx_bbavH9zsV5tKqdYk6uGAZdKWu663jLd9fJgUUKvtFPLvrTSlgJVl1m33IJSWrdKiq1jotZNfUZeHHWnGL7OkLK5CXP05Uoj6qZV5V8afY_a2QEM-j7kaN2IyZmVlloWJFsW1Pk_UGV1MKILHnos538RxJFQnKcUoTdTxNHGveHMHBI1x0RNSdT8StTcFtLzuxfP2xG6P5TfERZAfQSkMvI7iPeW_iP7E4udrUg</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Nafee, Noha</creator><creator>Gaber, Dina M.</creator><creator>Elzoghby, Ahmed O.</creator><creator>Helmy, Maged W.</creator><creator>Abdallah, Osama Y.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20200401</creationdate><title>Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles</title><author>Nafee, Noha ; Gaber, Dina M. ; Elzoghby, Ahmed O. ; Helmy, Maged W. ; Abdallah, Osama Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-80e1454a1cdfa07df407244ef57c56ff404a404e537dfd6be55779542bc023783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>A549 Cells</topic><topic>Administration, Inhalation</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - metabolism</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antioxidants</topic><topic>Antitumor activity</topic><topic>Biochemistry</topic><topic>Bioflavonoids</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Carcinoma</topic><topic>Cell Survival - drug effects</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Compounding</topic><topic>Drug Liberation</topic><topic>Drying</topic><topic>Flavones</topic><topic>Flavonoids</topic><topic>Flavonoids - administration & dosage</topic><topic>Flavonoids - metabolism</topic><topic>Flavonoids - pharmacology</topic><topic>Functional foods</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Lung cancer</topic><topic>Lung carcinoma</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Medical Law</topic><topic>Microparticles</topic><topic>Nanoparticles</topic><topic>Nanoparticles - chemistry</topic><topic>Nanotechnology</topic><topic>Particle Size</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Phospholipids</topic><topic>Phospholipids - chemistry</topic><topic>Physicochemical properties</topic><topic>Research Paper</topic><topic>Solubility</topic><topic>Surface active agents</topic><topic>Surface Properties</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nafee, Noha</creatorcontrib><creatorcontrib>Gaber, Dina M.</creatorcontrib><creatorcontrib>Elzoghby, Ahmed O.</creatorcontrib><creatorcontrib>Helmy, Maged W.</creatorcontrib><creatorcontrib>Abdallah, Osama Y.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nafee, Noha</au><au>Gaber, Dina M.</au><au>Elzoghby, Ahmed O.</au><au>Helmy, Maged W.</au><au>Abdallah, Osama Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles</atitle><jtitle>Pharmaceutical research</jtitle><stitle>Pharm Res</stitle><addtitle>Pharm Res</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>37</volume><issue>4</issue><spage>82</spage><pages>82-</pages><artnum>82</artnum><issn>0724-8741</issn><eissn>1573-904X</eissn><abstract>Purpose
Myricetin (MYR) flavonoid is well-recognized for its antioxidant, anti-inflammatory and anti-tumor potential. Introducing nanomedicine was the ultimate resort to solve the imperfections of this nutraceutical, namely solubility, stability and delivery issues. The study, thus, aims at developing inhalable microparticles comprising MYR solid lipid nanoparticles (SLNs) for lung cancer therapy.
Methods
A two-step preparation procedure starting with complexation of MYR with the phospholipid Lipoid-S100, followed by nanoencapsulation in Gelucire-based, surfactant-free SLNs was developed. SLNs were characterized in terms of physicochemical properties, MYR loading, release behavior as well as anti-tumor potential and cellular uptake. Respirable microparticles were then obtained by spray drying SLNs with carbohydrate carriers. Their size, flowability and pulmonary deposition pattern were assessed.
Results
Optimized SLNs were 75.98 nm in diameter with a zeta-potential of −22.5 mV, and an encapsulation efficiency of 84.5%. Attempts to ameliorate drug loading implicate MYR-phospholipid complexation (MYR-PH-CPX) prior to its entrapment in SLNs, which ensured 5-fold increase in drug loading. Viability assays were modified to guarantee MYR chemical stability. Superior antitumor activity of MYR-phospholipid-complex and 3-fold reduction in IC
50
were accomplished with MYR-SLNs. This could be related to enhanced cellular uptake revealed by confocal imaging and doubled fluorescence intensity. SLNs entrapping MYR-PH-CPX were spray-dried with carbohydrate carriers to produce respirable microparticles. The latter ensured MMAD of 2.39 μm and span index of 1.84, in addition to good flowability and > 80% release over 8 h. Deposition experiments revealed MMAD of 2.77 μm, FPF of 81.23 and EF of 93% indicating particle deposition in the targeted bronchial region.
Conclusions
The study highlights the ability of phospholipid-complex on the nanoencapsulation, cellular uptake and antitumor activity of MYR. Formulation of respirable microparticles gives promises of efficacious therapy of lung carcinoma.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32291520</pmid><doi>10.1007/s11095-020-02794-z</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-8741 |
| ispartof | Pharmaceutical research, 2020-04, Vol.37 (4), p.82, Article 82 |
| issn | 0724-8741 1573-904X |
| language | eng |
| recordid | cdi_proquest_journals_2389522987 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | A549 Cells Administration, Inhalation Antineoplastic Agents - administration & dosage Antineoplastic Agents - metabolism Antineoplastic Agents - pharmacology Antioxidants Antitumor activity Biochemistry Bioflavonoids Biomedical and Life Sciences Biomedical Engineering and Bioengineering Biomedicine Cancer Carcinoma Cell Survival - drug effects Drug Carriers - chemistry Drug Compounding Drug Liberation Drying Flavones Flavonoids Flavonoids - administration & dosage Flavonoids - metabolism Flavonoids - pharmacology Functional foods Humans Inflammation Lung cancer Lung carcinoma Lung Neoplasms - drug therapy Medical Law Microparticles Nanoparticles Nanoparticles - chemistry Nanotechnology Particle Size Pharmacology/Toxicology Pharmacy Phospholipids Phospholipids - chemistry Physicochemical properties Research Paper Solubility Surface active agents Surface Properties Tissue Distribution |
| title | Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A20%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Promoted%20Antitumor%20Activity%20of%20Myricetin%20against%20Lung%20Carcinoma%20Via%20Nanoencapsulated%20Phospholipid%20Complex%20in%20Respirable%20Microparticles&rft.jtitle=Pharmaceutical%20research&rft.au=Nafee,%20Noha&rft.date=2020-04-01&rft.volume=37&rft.issue=4&rft.spage=82&rft.pages=82-&rft.artnum=82&rft.issn=0724-8741&rft.eissn=1573-904X&rft_id=info:doi/10.1007/s11095-020-02794-z&rft_dat=%3Cgale_proqu%3EA747438906%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2389522987&rft_id=info:pmid/32291520&rft_galeid=A747438906&rfr_iscdi=true |